Counterpoint Quantitative Equity ETFCPAI

The CPAI ETF debuted this week with the kind of thematic language that makes issuers sound like they’ve cracked the Da Vinci Code of equity returns: "Counterpoint Quantitative Equity ETF offers investors exposure to large-cap U.S. equities selected through Counterpoint Global’s proprietary quantitative models." Translation: buy a fund that charges 0.49% per year to own the same stocks you could buy directly, except now you also own a fee. The Nasdaq listing confirms the ticker is live and trading in normal volumes, which is corporate finance’s way of saying "the plumbing works, but the magic is elsewhere."

Counterpoint Global, a Morgan Stanley Investment Management unit, has built a business on telling clients it can relative strength using data and models rather than stock-picking gut feel. The ETF wraps that promise in a 0.49% annual management fee and a 0.05% expense ratio, plus whatever the issuer tacks on for fund administration. The fund’s mandate is broad enough to include any large-cap U.S. company, which means the "quantitative" label is doing a lot of lifting while the holdings list is doing the heavy lifting of paying the bills. The Nasdaq page shows daily volume in the low thousands and a tight spread, which is good for traders but tells you nothing about whether Counterpoint’s models are any good at picking stocks beyond the marketing slide.

The SEC filings confirm the issuer is Counterpoint Global within Morgan Stanley Investment Management, and the fund is registered under the Investment Company Act of 1940. That’s the legal equivalent of a health-and-safety sticker on a toaster: required, but not a guarantee the toaster won’t burn your toast. The filings do not, however, disclose the actual holdings or weights in the basket, which is the entire point of buying the ETF in the first place. Until the first N-PORT filing lands, investors are flying blind on composition, concentration, and correlation risks. The FINRA Fund Analyzer calculates a total annual cost of 0.53%, which is cheaper than many active mutual funds but still a recurring toll on capital that compounds over time.

The Nasdaq ticker page shows CPAI trading with modest volume and a tight spread, which is the mechanical confirmation that the wrapper is functioning as an exchange-traded product. The chart route on Nasdaq shows a flat opening print and no intraday drama, which is par for the course when a new thematic ETF debuts with a mandate broad enough to include every large-cap stock in America. Without a live holdings list or performance track record, the only thing moving the price today is the fee-collection mechanism. The chart’s value is purely operational: it proves the ETF is tradable, not that it’s investable."

What changed this week is that CPAI now exists as a ticker, a quote, and a fee stream. What didn’t change is the investor’s ability to see what’s inside or whether Counterpoint’s quantitative approach adds value beyond the marketing. The issuer’s previous funds and strategies are documented in SEC filings, but those filings are backward-looking and do not disclose the current holdings or performance of CPAI. The Nasdaq listing confirms the wrapper is working; the rest remains a black box until the first portfolio disclosure lands."

The evidence we have today is thin but precise: the ticker is live, the fee is real, and the mandate is broad. What’s missing is the holdings list, the weights, and any performance history for CPAI itself. The next material source would be the issuer’s first N-PORT filing, which should disclose the portfolio composition and any concentration risks. Until then, CPAI is a fee wrapped around a promise, and the only certainties are the 0.49% management fee and the Nasdaq quote page."